Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. (2017)

First Author: Nieborowska-Skorska M
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood-2017-05-784942

PubMed Identifier: 29042365

Publication URI: http://europepmc.org/abstract/MED/29042365

Type: Journal Article/Review

Volume: 130

Parent Publication: Blood

Issue: 26

ISSN: 0006-4971